Earnings History Data for FibroGen, Inc (FGEN) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

FibroGen, Inc

FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious unmet medical needs. The Company develops Roxadustat that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; and FG-3019 which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis. FibroGen, Inc. is headquartered in San Francisco, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
12-11-2024	AH		FGEN	FibroGen, Inc	32.43	-0.17	-0.27	-0.52	FibroGen GAAP EPS of -$0.17 beats by $0.06, revenue of $46.3M beats by $11.54M [11/12/2024 4:25 PM]	0.3267	-0.06 (-15.49%)	0.42	0.03 (8.64%)	0.18 - 2.93	3,612,826	1,290,000	143,997
FibroGen GAAP EPS of -$0.17 beats by $0.06, revenue of $46.3M beats by $11.54M [11/12/2024 4:25 PM] FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions [2024-11-13 02:21AM] FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates [Nov-12-24 06:10PM] FibroGen: Q3 Earnings Snapshot [Nov-12-24 05:06PM] FibroGen Reports Third Quarter 2024 Financial Results [Nov-12-24 04:05PM] Q3 2024 FibroGen Inc Earnings Call [2024-11-13 10:22AM]
06-08-2024	AH		FGEN	FibroGen, Inc	46.75	-0.16	-0.25	-0.65	FibroGen GAAP EPS of -$0.16 beats by $0.20, revenue of $50.64M beats by $15.98M [8/6/2024 4:39 PM]	0.4699	0.03 (6.80%)	0.45	0.01 (2.41%)	0.33 - 2.93	2,273,945	4,220,000	66,816
FibroGen GAAP EPS of -$0.16 beats by $0.20, revenue of $50.64M beats by $15.98M [8/6/2024 4:39 PM]
06-05-2024	AH		FGEN	FibroGen, Inc	111.61	-0.33	-0.31	-0.81	FibroGen GAAP EPS of -$0.33 beats by $0.20, revenue of $55.9M beats by $19.45M [5/6/2024 4:07 PM]	1.38	0.22 (18.53%)	1.33	0.17 (14.66%)	0.33 - 19.47	27,594,576	1,200,000	6,087,308
FibroGen GAAP EPS of -$0.33 beats by $0.20, revenue of $55.9M beats by $19.45M [5/6/2024 4:07 PM]
26-02-2024	AH		FGEN	FibroGen, Inc	185.86	-0.57	-0.42	-0.70	FibroGen GAAP EPS of -$0.57 misses by $0.14, revenue of $27.14M misses by $11.64M [2/26/2024 4:10 PM]	2.13	0.28 (15.14%)	1.66	-0.19 (-10.27%)	0.33 - 23.53	2,720,855	2,570,000	241,676
FibroGen GAAP EPS of -$0.57 misses by $0.14, revenue of $27.14M misses by $11.64M [2/26/2024 4:10 PM] AstraZeneca returns right to roxadustat to FibroGen [2/26/2024 4:25 PM]
06-11-2023	AH		FGEN	FibroGen, Inc	55.69	-0.52	-0.68	-0.98	FibroGen GAAP EPS of -$0.65 beats by $0.02, revenue of $40.1M beats by $3.26M [11/6/2023 4:07 PM]	0.5457	-0.01 (-2.41%)	0.65	0.09 (16.24%)	0.47 - 25.69	2,560,528	1,540,000	46,343
FibroGen GAAP EPS of -$0.65 beats by $0.02, revenue of $40.1M beats by $3.26M [11/6/2023 4:07 PM]
07-08-2023	AH		FGEN	FibroGen, Inc	183.45	-0.65	-0.72	-0.78	FibroGen GAAP EPS of -$0.90 misses by $0.16, revenue of $44.32M beats by $9.53M [8/7/2023 4:28 PM]	1.43	-0.34 (-19.21%)	1.78	0.01 (0.56%)	1.41 - 25.69	7,703,875	2,790,000	32,981
FibroGen GAAP EPS of -$0.90 misses by $0.16, revenue of $44.32M beats by $9.53M [8/7/2023 4:28 PM]
08-05-2023	AH	4:00 PM ET (May 8)	FGEN	FibroGen, Inc	1,570	-0.81	-0.76	-0.68	FibroGen GAAP EPS of -$0.81 misses by $0.02, revenue of $36.16M beats by $4.64M [5/8/2023 4:41 PM]	17.48	-0.29 (-1.63%)	17.77	0.0 (0.00%)	7.81 - 25.69	645,891	1,080,000	9,148
FibroGen GAAP EPS of -$0.81 misses by $0.02, revenue of $36.16M beats by $4.64M [5/8/2023 4:41 PM]
27-02-2023	AH	4:00 PM ET (Feb 27)	FGEN	FibroGen, Inc	2,120	-0.70	-0.95	-1.45	FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M [2/27/2023 4:02 PM]	22.25	-0.27 (-1.18%)	22.51	0.0 (0.00%)	7.81 - 25.69	1,529,637	760,000	250,154
FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M [2/27/2023 4:02 PM]
07-11-2022	AH	4:00 PM ET (Nov 7)	FGEN	FibroGen, Inc	1,540	-0.98	-0.83	0.54	FibroGen GAAP EPS of -$0.98 misses by $0.16, revenue of $15.7M misses by $15.89M [11/7/2022 4:03 PM]	14.15	-2.01 (-12.44%)	16.16	0.0 (0.00%)	7.81 - 18.31	1,442,893	670,000	140,391
FibroGen GAAP EPS of -$0.98 misses by $0.16, revenue of $15.7M misses by $15.89M [11/7/2022 4:03 PM]
08-08-2022	AH	4:00 PM ET (Aug 8)	FGEN	FibroGen, Inc	1,150	-0.78	-0.94	-1.45	FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34M [8/8/2022 4:04 PM]	14.18	-0.42 (-2.88%)	14.60	0.0 (0.00%)	7.81 - 16.91	659,838	670,000	55,631
FibroGen GAAP EPS of -$0.78 beats by $0.19, revenue of $29.81M misses by $6.34M [8/8/2022 4:04 PM]
09-05-2022	AH	4:00 PM ET (May 9)	FGEN	FibroGen, Inc	829.37	-0.68	-0.84	-0.78	FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M [5/9/2022 4:04 PM]	10.24	2.30 (29.03%)	8.60	0.66 (8.31%)	7.81 - 30.12	1,687,860	763,118	1,263
FibroGen GAAP EPS of -$0.68 beats by $0.24, revenue of $60.8M beats by $32.04M [5/9/2022 4:04 PM] FibroGen stock jumps as strong roxadustat sales help drive Q1 earnings beat [5/10/2022 1:31 PM] ImmunoGen (IMGN) Reports Q1 Loss, Tops Revenue Estimates [May-06-22 07:45AM] FibroGen Reports First Quarter 2022 Financial Results [May-09-22 04:01PM] FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates [May-09-22 05:25PM]
28-02-2022	AH	4:00 PM ET (Feb 28)	FGEN	FibroGen, Inc	1,370	-1.45	-0.68	-0.64	FibroGen GAAP EPS of -$1.45 misses by $0.74, revenue of $16.54M misses by $31.11M [2/28/2022 4:04 PM]	13.61	-0.46 (-3.27%)	13.00	-1.07 (-7.60%)	9.88 - 52.03	1,647,034	710,000	3,947
FibroGen GAAP EPS of -$1.45 misses by $0.74, revenue of $16.54M misses by $31.11M [2/28/2022 4:04 PM] FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-28-22 04:01PM] FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:45PM]
09-11-2021	AH	4:00 PM ET (Nov 9)	FGEN	FibroGen, Inc	1,190	0.54	0.09	0.35	FibroGen EPS beats by $0.33, beats on revenue [11/9/2021 4:03 PM]	12.18	0.10 (0.83%)	12.85	0.77 (6.37%)	9.88 - 57.21	977,548	880,000	8,109
FibroGen EPS beats by $0.33, beats on revenue [11/9/2021 4:03 PM] FibroGen Reports Third Quarter 2021 Financial Results [Nov-09-21 04:01PM] FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates [Nov-09-21 05:15PM] FibroGen, inc (FGEN) Q3 2021 Earnings Call Transcript [Nov-10-21 01:01AM] S.F. biotech cutting 100 positions as it awaits U.S. fate of anemia drug [Nov-10-21 05:32PM]
09-08-2021	AH	4:00 PM ET (Aug 9)	FGEN	FibroGen, Inc	1,280	-1.45	-0.48	-0.95	FibroGen EPS misses by $0.98, misses on revenue [8/9/2021 4:12 PM]	13.20	-0.59 (-4.28%)	13.34	-0.45 (-3.26%)	12.54 - 57.21	1,725,430	900,000	12,692
FibroGen EPS misses by $0.98, misses on revenue [8/9/2021 4:12 PM] FibroGen Reports Second Quarter 2021 Financial Results [Aug-09-21 04:01PM] FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates [Aug-09-21 05:15PM] FibroGen, inc (FGEN) Q2 2021 Earnings Call Transcript [Aug-10-21 02:00AM] FibroGen Stock Is Dropping Again as Hopes Fade for Anemia Drug [Aug-10-21 08:23AM]
10-05-2021	AH	4:00 PM ET (May 10)	FGEN	FibroGen, Inc	1,900	-0.78	-0.90	-0.89	FibroGen EPS beats by $0.09, misses on revenue [5/10/2021 4:14 PM]	20.14	0.72 (3.68%)	19.00	-0.42 (-2.16%)	18.12 - 57.21	1,469,356	880,000	6,209
FibroGen EPS beats by $0.09, misses on revenue [5/10/2021 4:14 PM] SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits [May-07-21 10:40PM] Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. Expanded Class Period [May-07-21 07:05PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel [May-07-21 06:47PM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of VRM, GOEV and FGEN [May-07-21 05:55PM] Berman Tabacco Announces June 11, 2021 Deadline For Lead Plaintiff Motions In Its Securities Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN) In the Northern District of California [May-07-21 05:00PM] LAWSUITS FILED AGAINST VRM, FGEN and CCXI - Jakubowitz Law Pursues Shareholders Claims [May-07-21 04:30PM] FIBROGEN SHAREHOLDERS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser [May-07-21 03:15PM] SHAREHOLDER ALERT: GOEV FGEN RMO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [May-07-21 12:20PM] DEADLINE ALERT for DDD, DOX, SHRMF, FGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders [May-07-21 12:00PM] ACAD, FGEN, RMO INVESTOR ALERT: HAGENS BERMAN, National Trial Attorneys, Updates ACAD, FGEN, RMO Investors on Securities Class Actions and Application Deadlines, Encourages Investors with Losses to Contact the Firm [May-07-21 11:20AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FGEN, PTON and CCXI [May-07-21 10:15AM] FIBROGEN SHAREHOLDERS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser [May-07-21 09:30AM] Why Earnings Season Could Be Great for FibroGen (FGEN) [May-07-21 08:45AM] CLASS ACTION UPDATE for VRM, FGEN and CAN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-07-21 05:40AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BLU, KDMN and FGEN [May-10-21 06:20AM] The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. [May-10-21 12:18PM] SHAREHOLDER ALERT: VRM KRMD FGEN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [May-10-21 12:00PM] Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for FibroGen, Inc. Investors - Expanded Class Period [May-10-21 11:20AM] ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits Filed on Behalf of CCXI, DOX, FGEN, GOEV Investors, Lead Plaintiff Deadlines Set [May-10-21 12:40PM] Lawsuits Filed Against CYDY, GOEV and FGEN - Jakubowitz Law Pursues Shareholders Claims [May-10-21 01:20PM] FibroGen, Inc. to Host Earnings Call [May-10-21 02:45PM] FGEN INVESTORS WHO LOST MONEY; HAGENS BERMAN, National Trial Attorneys, Alerts FibroGen (FGEN) Investors to Securities Class Action, Encourages Investors with Losses to Contact the Firm Now [May-10-21 03:29PM] FibroGen Reports First Quarter 2021 Financial Results [May-10-21 04:01PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CYDY, KDMN and FGEN [May-10-21 04:00PM] FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 05:45PM] ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FGEN [May-10-21 08:51PM] FibroGen Inc (FGEN) Q1 2021 Earnings Call Transcript [May-10-21 09:30PM] SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits [May-10-21 11:15PM] CLASS ACTION UPDATE for RIDE, VRM and FGEN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-11-21 06:15AM] SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. [May-11-21 08:40AM] HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel [May-11-21 09:19AM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ROOT, FGEN and CCXI [May-11-21 09:30AM] FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser [May-11-21 09:45AM] FGEN, CAN & RMO Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm [May-11-21 11:00AM] SHAREHOLDER ALERT: CYDY NEPT FGEN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines [May-11-21 11:30AM] Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN) [May-11-21 12:54PM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ROOT, GOEV and FGEN [May-11-21 01:35PM] FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Shareholders of Securities Fraud Class Action Lawsuit [May-11-21 06:51PM] SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN [May-11-21 06:39PM] FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm [May-11-21 06:29PM] CLASS ACTION UPDATE for ACAD, FGEN, RMO: Hagens Berman Updates Investors on Securities Class Actions, Advises Investors with Losses to Contact the Firm [May-11-21 05:05PM] FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders [May-11-21 08:25PM]
01-03-2021	AH	4:00 PM ET (Mar 1)	FGEN	FibroGen, Inc	4,540	-0.64	-0.29	-1.12	FibroGen EPS misses by $0.38, misses on revenue [3/1/2021 4:12 PM]	38.34	-12.19 (-24.12%)	38.10	-12.43 (-24.60%)	22.65 - 57.21	10,140,047	592,131	337,548
FibroGen EPS misses by $0.38, misses on revenue [3/1/2021 4:12 PM] FDA to hold AdCom meet to review FibroGen, AstraZeneca's kidney drug [3/2/2021 3:18 AM] FibroGen shares plummet 24% as FDA meeting, Jefferies downgrade weigh [3/2/2021 9:28 AM] The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data [Mar-02-21 08:01AM] FibroGen Tumbles on Earnings Miss, FDA Meeting Notice [Mar-02-21 06:40AM] FibroGen Inc (FGEN) Q4 2020 Earnings Call Transcript [Mar-02-21 05:01AM] FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results [Mar-01-21 04:01PM] FibroGen Provides Regulatory Update on Roxadustat [Mar-01-21 04:01PM] FibroGen, Inc. to Host Earnings Call [Mar-01-21 03:15PM]
05-11-2020	AH	4:00 PM ET (Nov 5)	FGEN	FibroGen, Inc	3,620	0.35	-0.89	-0.57	FibroGen EPS beats by $1.09, misses on revenue [11/5/2020 4:31 PM]	41.29	-1.17 (-2.76%)	41.80	-0.66 (-1.55%)	22.65 - 51.56	360,600	721,478	3,400

06-08-2020	AH	4:00 PM ET (Aug 6)	FGEN	FibroGen, Inc	3,780	-0.95	-0.59	1.26	FibroGen EPS misses by $0.39, misses on revenue [8/6/2020 4:40 PM]	44.89	3.44 (8.30%)	41.50	0.05 (0.12%)	22.65 - 48.95	671,535	406,059	202